Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis.
acute severe colitis
sequential therapy
tofacitinib
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
19
12
2022
accepted:
04
05
2023
medline:
22
8
2023
pubmed:
21
8
2023
entrez:
20
8
2023
Statut:
ppublish
Résumé
Acute severe colitis (ASUC) remains a significant cause of morbidity in up to 25% of patients with ulcerative colitis during their disease course. We present the outcomes out to 12 months following the use of high-dose tofacitinib, 10 mg three times daily (TDS), in patients with steroid and infliximab refractory ASUC. A total of 11 patients with ASUC who were treated with high-dose tofacitinib after failing sequential infliximab therapy between 2019 and 2021 were identified at an Australian tertiary centre. Ten of 11 patients demonstrated clinical and biochemical response to treatment during admission. Two of 11 patients required colectomy, one during the index admission and the other during re-admission 10 days after the index presentation. Nine of the initial responders had a median Mayo score of 1 (IQR 0-4) at both 6 and 12 months, and all remained colectomy-free out to 12 months. Neither venous thromboembolic events nor major infective complications were observed. Tofacitinib may be a safe and effective induction and maintenance agent in the treatment of steroid and infliximab refractory ASUC. Prospective studies with long-term follow-up are required to explore the use of tofacitinib in ASUC before it can be routinely recommended as salvage therapy.
Substances chimiques
Infliximab
B72HH48FLU
tofacitinib
87LA6FU830
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1497-1500Informations de copyright
© 2023 Royal Australasian College of Physicians.
Références
Dinesen LC, Walsh AJ, Protic MN, Heap G, Cummings F, Warren BF et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010; 4: 431-437.
Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-110.
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. The Lancet 2012; 380: 1909-1915.
Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376: 1723-1736.
Gilmore R, Hilley P, Srinivasan A, Choy M, de Cruz P. Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis. J Crohns Colitis 2022; 16: 166-168.
Berinstein JA, Steiner CA, Regal RE, Allen JI, Kinnucan JAR, Stidham RW et al. Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2019; 17: 988-990.e1.
Kotwani P, Terdiman J, Lewin S. Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience. J Crohns Colitis 2020; 14: 1026-1028.
Berinstein JA, Sheehan JL, Dias M, Berinstein EM, Steiner CA, Johnson LA et al. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol 2021; 19: 2112-2120.e1.
Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S et al. Tofacitinib, an Oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624.
Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Iii. Complications. Gut 1964; 5: 1-22.
Travis SPL, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MGW et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910.